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Kazakhstan is an upper-middle-income country with per capita GDP of nearly 
US$13 thousand in 2013. Kazakh’s public healthcare system – UNHS (Unified 
National Health System) – aims to deliver healthcare coverage to the whole popu-
lation. The political desire of authorities to provide broader access to healthcare 
for its populations, along with the growing prevalence of non-communicable dis-
eases (NCDs) such as cardiovascular disease, cancer and diabetes, are placing a 
strain not only on government budget but also on the healthcare infrastructure 
in Kazakhstan. Increasing life expectancy is giving rise to the greater burden 
associated with ageing populations, while governments struggle to balance grow-
ing costs with a need to expand healthcare provision to all. At the heart of any 
cost-containment strategy is a set of tools, ranging from complex risk-sharing 
schemes and health technology assessment (HTA) through to more simplistic 
mechanisms, such as prescribing controls and mandatory price cuts. Analysis of 
cost-management trends in Kazakhstan, relative with international experience, 
suggests a leaning towards less complex approaches. One reason for this is that 
before being able to even contemplate more sophisticated initiatives, governments 
must first address basic infrastructure needs. These include having sufficient doc-
tors and clinics to diagnose and treat patients. There is growing appreciation that 
cost containment can only be effective when implemented in a systematic man-
ner. Kazakhstan already have informal guidelines in place and are now consid-
ered «mature» markets in terms of HTA adoption. Despite the obvious challenges, 
some would argue that the time for HTA has arrived in Kazakhstan. Implemented 
correctly, it can play a role in the future of the region, not only as a key compo-
nent of cost containment but also as a pivotal enabler for the efficient use of 
resources, as governments look to provide broader access to affordable healthcare 
for all.
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Objectives: This conceptual paper aims to build a roadmap to reach integrated 
healthcare (HC) system in Egypt for optimum efficiency and utilization of resources 
among the different insurance bodies. The roadmap will help fill in the gaps 
evolved from the fragmented system having 5 different types of insurance cov-
erage. MethOds: Gap analysis between the desired integrated HC system that 
achieves; Equity, Solidarity and Free access to entire population, and the current 
situation of the HC system which was obtained from interviews and discussions 
with the HC payers and decision makers inside the public sector. Results: A 
ten year roadmap was built with eight action steps that were identified to reach 
integrated HC system: 1- Task Force Committee: from inside and outside the 
public sectors, 2- Research and Data centre: responsible for Epidemiological and 
Pharmacoepidemiological studies, 3- Prioritization plan: prioritize coverage plan 
based on budget and strategic diseases burden , 4- Treatment Protocols Flowchart: 
ensuring unified treatment guidelines across different HC bodies 5-Unique 
Patient ID: thus all insured patients are traceable without double counts, 6- Health 
Information System: connecting all HC units for optimum resources utilization, 
7- Primary Care Physicians Development Plan: continuous education programs 
for optimizing their utilization and freeing time to the over-utilized special-
ists, 8- Health Economics Unit: that will be the nucleus of establishing a Health 
Technology Assessment body responsible for economical strategic planning of the 
HC. RecOMMendAtiOns: Although some action steps were taken in some of the 
mentioned points however they were executed as separate initiatives inside the 
public sector; therefore it’s of high importance that the taskforce committee takes 
the accountability of executing the project as a single mission, and make sure the 
executed action steps are utilized and integrated with the rest of action steps as 
per the roadmap timetable.
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Objectives: The health care system reforms, which in many countries, par-
ticularly in the Eastern Europe, started in the 1990s, affected Latvia as well. The 
directions of the reforms can be divided into two basic segments – health care 
system organisation and health care system financing. Within the framework of 
this research, the author evaluates the health system research opportunities to 
assess the efficiency of the health care system reform in Latvia. MethOds: To 
achieve the goal of the research, the methods of the theoretical research are used 
alongside the methods of empirical research. The methods of statistical analy-
sis and methods of economic analysis are used for data processing and analy-
sis. Results: To perform the research, the author uses a three-level performance 
evaluation model based on macro-level evaluation, meso-level evaluation, and 
micro-level evaluation. The appropriate measures of the macro impact results, 
policy outcomes and performance outputs are defined to evaluate the effective-
ness of the performed health care system reform. The author assumes that the 
macro impact results are specified for public health, the policy outcomes are 
determined for the health care, as well as the pharmacy, while the performance’s 
outputs are representative for all areas. cOnclusiOns: The general conclusions 
show, for example, that the economic efficiency of the reimbursement system is 
sufficient and at the same time there is a tendency to move towards technical 
efficiency rather than total economic efficiency (technical and allocative effi-
ciency). The allocative efficiency in health economics is also associated with the 
market efficiency and effectiveness of the treatment process. However, the author 
notes that there are no perfect competition market conditions for health care 
products and services, so it is necessary to use alternative methods of economic 
analysis.
are completely damaged where others have been left with endangered to work in. 
The damaged infrastructure has left with inability to store essential drugs and vac-
cines. The cost of building new health care facilities is expected to reach billions of 
dollars. The cost required for the acute trauma is estimated very high. As homeless 
people are living in improper shelter, they have been presenting with other health 
related problems. For the short term relief, disaster management team should be 
formed in major government hospitals and medical colleges taking help of army and 
police health care personnel. Immediate enrolment of medical officers at the level 
of primary health centers should be done. A blend with major government and non-
government organizations like International Red Cross, United Nations Organization, 
World Health Organization, USAID etc. should be made to meet the health care equip-
ment, trained manpower and all other expenses. For the long term relief, trauma cent-
ers should be established in regional levels. As most of the remote villages even don’t 
have primary health centers, the health and sub health posts should be upgraded to 
meet the demands. Health posts and sub health posts should engage at least medical 
officers backed up by supportive staffs and basic investigations.
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bAckgROund: Market access for pharmaceuticals is evolving in a fast-changing 
environment : (1)Pressure of European Union (EU) Member States (MS) on health 
insurance budgets; (2) Dramatic technological advances; targeting new biological 
pathways, advanced therapy medicinal products, personalized medicines, expansion 
of digital medicine; (3) Initiatives from regulators and payers to develop synergies, 
e.g., collaborations between HTA agencies and multi-HTA/parallel early advice; (4) 
Increased payer risk-aversion and increasing products with limited information at 
launch; (5) Healthcare organisations moving towards integrated healthcare services 
(6) Ageing population and growing prevalence of chronic conditions, co-morbidi-
ties, and life threatening diseases; (7) Increased access inequity between EU MS. 
discussiOn: Cost-containment measures will increase under close supervision 
of parliaments. Fast development of electronic communication will allow online 
monitoring of drug utilisation. Adaptive licensing and limited evidence at time of 
launch will lead to generalization of coverage with evidence development. A more 
pragmatic approach in clinical trial designs should be considered to cope with con-
comitant development of companion diagnostics, segmentation of treated patients 
with targeted therapies; adaptive pathways should evolve from pilot to standard 
approach. Post-launch observational studies will become unavoidable to meet regu-
lators and payers’ expectations. Pan-European HTA coordination could lead to one 
single European HTA body assessing drugs prior to national HTA and pricing and 
reimbursement process. Managed entry agreements, ambulatory DRG, and bundled 
payments might become standard models. Integrated health services will expand, 
shifting payers role to health care providers. Differential pricing will address access 
inequity. cOnclusiOn: Sustainability of healthcare systems will remain at the 
heart of drug funding decisions. Drug market access will evolve through extended 
collaborations and interactions between key stakeholders. Drug licensing, pricing 
and reimbursement decisions will be increasingly coordinated to enable fast patient 
access to innovative therapies. Real-world data will be central to switch from initial 
restricted access to progressive wider coverage.
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bAckgROund: Adaptive pathways (AP) are prospective planned approaches to regula-
tion and coverage of drugs. Through iterative phases of evidence gathering, it aims to 
reduce uncertainties while balancing timely access for patients and level of available 
evidence. The concept assumes that all phases from development to clinical routine 
use through reimbursement are integrated. If AP did develop from regulatory per-
spective, many payers remain resistant. The aim of this research is to discuss payer’s 
position on AP. discussiOn: Payers show an increasing resistance to uncertainty and 
their decisions are mainly driven by evidence robustness. Regulators are integrating 
foregone alternative treatment opportunities in decision making and increasingly 
registering drugs with limited evidence and larger benefit estimates. Time from devel-
opment initiation to marketing authorization (MA) decreases overtime (compassionate 
use, accelerated assessment, conditional MA, MA under exceptional circumstances); 
On the opposite, time from MA to reimbursement expand with an increasing number 
of products denied reimbursement due to limited evidence. This gap between regula-
tors and payers continues to increase and AP may widen this gap. While managed 
entry agreements were thought to help managing uncertainty, it happens, in most of 
the cases, to be used as disguised cost-containment tools. Only coverage with evidence 
development (CED) with escrow agreements remain an appropriate tool to address 
uncertainty, but is rarely used. The difficulty to reverse reimbursement decision makes 
payers very sensitive to uncertainty. AP is unlikely to address the payers concern unless 
they are directly involved in identifying risk, designing mitigation plan, and moni-
toring the uncertainty. cOnclusiOn: AP may contribute to widen the gap between 
regulators and payers. Only CED with escrow agreement may be an appropriate tool 
to address payers’ uncertainty. However, AP pilot projects with expected high benefit 
will exercise pressure on payers to issue reimbursement.
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